Bevacizumab

• 

  Subject Areas on Research

  • 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). 
  • A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema. 
  • A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. 
  • A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme. 
  • A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. 
  • A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. 
  • A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies. 
  • A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. 
  • A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. 
  • A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). 
  • A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. 
  • A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. 
  • A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. 
  • A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. 
  • A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. 
  • A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. 
  • A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. 
  • A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. 
  • A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. 
  • A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. 
  • A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). 
  • A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. 
  • A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. 
  • AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma. 
  • ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer. 
  • Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. 
  • Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. 
  • Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial. 
  • Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. 
  • Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. 
  • Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. 
  • Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. 
  • Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. 
  • Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. 
  • An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204). 
  • An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumab. 
  • An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone. 
  • Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. 
  • Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. 
  • Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions. 
  • Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. 
  • Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 
  • Anti-angiogenic therapy for high-grade glioma. 
  • Anti-angiogenic therapy in renal cell cancer. 
  • Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. 
  • Antiangiogenic therapy for high-grade glioma. 
  • Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. 
  • Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. 
  • Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. 
  • Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy. 
  • Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. 
  • Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. 
  • Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. 
  • Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). 
  • Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. 
  • Association of Pediatric Choroidal Neovascular Membranes at the Temporal Edge of Optic Nerve and Retinochoroidal Coloboma. 
  • Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. 
  • Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma. 
  • Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. 
  • Autosomal recessive best vitelliform macular dystrophy: report of a family and management of early-onset neovascular complications. 
  • Avastin: more questions than answers. . . 
  • BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). 
  • Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study. 
  • Baseline Factors Associated With 6-Month Visual Acuity and Retinal Thickness Outcomes in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Study Report 4. 
  • Best practices for treatment of retinal vein occlusion. 
  • Bevacizumab for the treatment of high-grade glioma. 
  • Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. 
  • Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). 
  • Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. 
  • Bevacizumab and daily temozolomide for recurrent glioblastoma. 
  • Bevacizumab and everolimus in renal cancer: a rational way forward. 
  • Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter? 
  • Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). 
  • Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. 
  • Bevacizumab biosimilars: scientific justification for extrapolation of indications. 
  • Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. 
  • Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. 
  • Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. 
  • Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration. 
  • Bevacizumab for patients with metastatic renal cancer: an update. 
  • Bevacizumab for retinopathy of prematurity. 
  • Bevacizumab for the treatment of high-grade glioma: an update after phase III trials. 
  • Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. 
  • Bevacizumab in colorectal cancer. 
  • Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. 
  • Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective? 
  • Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. 
  • Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. 
  • Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. 
  • Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. 
  • Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. 
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. 
  • Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. 
  • Bevacizumab therapy for glioblastoma: a passionate discussion. 
  • Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status. 
  • Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. 
  • Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. 
  • Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. 
  • Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. 
  • Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. 
  • Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. 
  • Bevacizumab: radiation combination produces restricted diffusion on brain MRI. 
  • Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus. 
  • Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. 
  • CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties. 
  • CENTRAL RETINAL VEIN OCCLUSION IN YOUNG INDIVIDUALS: A Comparison of Risk Factors and Clinical Outcomes. 
  • CORRELATION OF SUBRETINAL HYPERREFLECTIVE MATERIAL MORPHOLOGY AND VISUAL ACUITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. 
  • Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. 
  • Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. 
  • Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. 
  • Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme. 
  • Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial. 
  • Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. 
  • Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. 
  • Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study. 
  • Choroidal neovascularization in a child with infantile primary hyperoxaluria treated with bevacizumab. 
  • Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. 
  • Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. 
  • Colon cancer, version 3.2014. 
  • Combinations of Bevacizumab With Cancer Immunotherapy. 
  • Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. 
  • Combined modality treatment for rectal cancer. 
  • Combined-modality therapy for rectal cancer: future prospects. 
  • Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria). 
  • Combining targeted agents with modern radiotherapy in soft tissue sarcomas. 
  • Comparison of Monthly vs Treat-and-Extend Regimens for Individuals With Macular Edema Who Respond Well to Anti-Vascular Endothelial Growth Factor Medications: Secondary Outcomes From the SCORE2 Randomized Clinical Trial. 
  • Comparison of Visual Outcomes in Coats' Disease: A 20-Year Experience. 
  • Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients. 
  • Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. 
  • Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. 
  • Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. 
  • Corneal penetration of topical and subconjunctival bevacizumab. 
  • Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab. 
  • Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. 
  • Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). 
  • Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models. 
  • Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. 
  • Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. 
  • Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis). 
  • Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. 
  • Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. 
  • Differences in Presentation and Outcomes in Males and Females With Branch Retinal Vein Occlusion. 
  • Differential effects of triamcinolone and bevacizumab in central retinal vein occlusion. 
  • Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma. 
  • Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. 
  • Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. 
  • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. 
  • Discontinuation and loss to follow-up rates in clinical trials of intravitreal anti-vascular endothelial growth factor injections. 
  • Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. 
  • Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye. 
  • Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab. 
  • Dynamic contrast-enhanced MR microscopy identifies regions of therapeutic response in a preclinical model of colorectal adenocarcinoma. 
  • Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters. 
  • Dynamic fractal signature dissimilarity analysis for therapeutic response assessment using dynamic contrast-enhanced MRI. 
  • Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. 
  • Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment. 
  • Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. 
  • Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. 
  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. 
  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. 
  • Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. 
  • Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. 
  • Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. 
  • Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. 
  • Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. 
  • Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. 
  • Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. 
  • Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. 
  • Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. 
  • Endoglin interacts with VEGFR2 to promote angiogenesis. 
  • Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections. 
  • Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. 
  • Evaluation of hypertension as a marker of bevacizumab efficacy. 
  • Evaluation of subconjunctival bevacizumab as an adjunct to trabeculectomy a pilot study. 
  • Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). 
  • Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity. 
  • Eyes With Acute, Treatment-Naïve CRVO and Foveal Intraretinal Hemorrhage: Characteristics and Outcomes. 
  • Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). 
  • Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. 
  • Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). 
  • Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. 
  • Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). 
  • Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. 
  • Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. 
  • Hidden biases in an observational study of bevacizumab beyond progression. 
  • Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. 
  • IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. 
  • Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). 
  • Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. 
  • Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress. 
  • Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). 
  • Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. 
  • Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. 
  • Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Incidence and Progression of Nongeographic Atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Clinical Trial. 
  • Incidence of retinal artery occlusion following intravitreal antivascular endothelial growth factor injections. 
  • Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). 
  • Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. 
  • Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. 
  • Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration. 
  • Intravitreal Pharmacotherapies for Diabetic Macular Edema: A Report by the American Academy of Ophthalmology. 
  • Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. 
  • Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment. 
  • Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. 
  • Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases. 
  • Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. 
  • Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. 
  • Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration. 
  • Long-term treatment with bevacizumab for patients with metastatic colorectal cancer: case report. 
  • Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. 
  • Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. 
  • Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. 
  • Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). 
  • Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability. 
  • Making genuine progress against metastatic breast cancer. 
  • Management of glioblastoma: State of the art and future directions. 
  • Management of hearing in pediatric NF2. 
  • Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. 
  • Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. 
  • Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105. 
  • Molecular markers for incidence, prognosis, and response to therapy. 
  • Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century? 
  • Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study. 
  • Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. 
  • Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. 
  • Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. 
  • Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. 
  • Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment. 
  • New combinations in metastatic colorectal cancer: what are our expectations? 
  • Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. 
  • Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab. 
  • Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. 
  • Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. 
  • Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. 
  • Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). 
  • Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor. 
  • Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor. 
  • PET concerns in bevacizumab treatment. 
  • PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. 
  • Palliative treatment of metastatic colorectal cancer: what is the optimal approach? 
  • Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. 
  • Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer. 
  • Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer. 
  • Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. 
  • Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. 
  • Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. 
  • Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. 
  • Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. 
  • Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. 
  • Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. 
  • Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). 
  • Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. 
  • Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma. 
  • Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. 
  • Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. 
  • Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. 
  • Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. 
  • Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. 
  • Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. 
  • Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. 
  • Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. 
  • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. 
  • Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. 
  • Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. 
  • Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. 
  • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. 
  • Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. 
  • Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. 
  • Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept. 
  • Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants. 
  • Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. 
  • Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance). 
  • Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. 
  • Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. 
  • Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. 
  • Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. 
  • Primary systemic therapy in HER2-amplified breast cancer: a clinical review. 
  • Primary tumor location as a prognostic factor in metastatic colorectal cancer. 
  • Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). 
  • Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. 
  • Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686. 
  • Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. 
  • Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity. 
  • Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. 
  • Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. 
  • Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. 
  • Quality of life in ICON7: need for patients' perspectives. 
  • Quantification of Change in Pigment Epithelial Detachment Volume and Morphology After Transition to Intravitreal Aflibercept in Eyes With Recalcitrant Neovascular AMD: 18-Month Results. 
  • Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. 
  • Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. 
  • Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. 
  • Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). 
  • Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. 
  • Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study. 
  • Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. 
  • Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. 
  • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. 
  • Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results. 
  • Ranibizumab and bevacizumab for neovascular age-related macular degeneration. 
  • Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. 
  • Rapid regression of retinal neovascularization following intravitreal bevacizumab in branch retinal vein occlusion imaged by optical coherence tomography angiography. 
  • Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer. 
  • Recurrent malignant gliomas. 
  • Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. 
  • Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme? 
  • Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. 
  • Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. 
  • Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. 
  • Rhegmatogenous Retinal Detachment after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor. 
  • Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. 
  • Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. 
  • SHORT-TERM COMPUTER-ASSISTED QUANTIFICATION OF PLUS DISEASE AFTER TREATMENT OF TYPE 1 RETINOPATHY OF PREMATURITY WITH INTRAVITREAL BEVACIZUMAB OR RETINAL LASER PHOTOCOAGULATION. 
  • Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. 
  • Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study. 
  • Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. 
  • Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. 
  • Safety of bevacizumab in patients with metastatic breast cancer. 
  • Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity. 
  • Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. 
  • Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. 
  • Slow progressive perifoveal vascular formation in an infant with aggressive posterior retinopathy of prematurity. 
  • Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme. 
  • Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. 
  • Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. 
  • Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. 
  • Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. 
  • Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases. 
  • Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. 
  • TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 
  • Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. 
  • Targeted therapies for cancer 2004. 
  • Targeted therapy of colorectal cancer: clinical experience with bevacizumab. 
  • Targeting CXCR4-dependent immunosuppressive Ly6Clow monocytes improves antiangiogenic therapy in colorectal cancer. 
  • Targeting the future in head and neck cancer. 
  • Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. 
  • Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. 
  • The Evolution of Fibrosis and Atrophy and Their Relationship with Visual Outcomes in Asian Persons with Neovascular Age-Related Macular Degeneration. 
  • The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab. 
  • The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. 
  • The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. 
  • The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. 
  • The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). 
  • The paradoxical effect of bevacizumab in the therapy of malignant gliomas. 
  • The role of targeted therapy in the treatment of colorectal cancer. 
  • The treatment of colorectal carcinoma: standard chemotherapy and beyond. 
  • The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. 
  • The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. 
  • Three-dimensional pattern of extraretinal neovascular development in retinopathy of prematurity. 
  • Topical bevacizumab therapy for corneal neovascularization. 
  • Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results. 
  • Treating age-related macular degeneration: comparing the use of two drugs among medicare and veterans affairs populations. 
  • Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? 
  • Treatment of age-related macular degeneration. 
  • Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. 
  • Treatment options in renal cell carcinoma: past, present and future. 
  • Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. 
  • Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. 
  • Trends in Anti-Vascular Endothelial Growth Factor Agents and Panretinal Photocoagulation Use in Diabetic Retinopathy. 
  • Trends in age-related macular degeneration management in Singapore. 
  • Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. 
  • Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy. 
  • Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective. 
  • Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. 
  • Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. 
  • Use of bevacizumab in recurrent glioblastoma. 
  • VEGF inhibition and renal thrombotic microangiopathy. 
  • Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial. 
  • Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. 
  • Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. 
  • Ziv-aflibercept: binding to more than VEGF-A--does more matter? 
  • [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. 
• 

  Keywords of People

  • McCall, Shannon Jones, Associate Professor of Pathology, Pathology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Uronis, Hope Elizabeth, Associate Professor of Medicine, Medicine, Medical Oncology
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society